Biodexa Pharmaceuticals Plc (BDRX)
BDRX Stock Price Chart
Explore Biodexa Pharmaceuticals Plc interactive price chart. Choose custom timeframes to analyze BDRX price movements and trends.
BDRX Company Profile
Discover essential business fundamentals and corporate details for Biodexa Pharmaceuticals Plc (BDRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Dec 2015
Employees
13.00
Website
https://www.biodexapharma.comCEO
Stephen Anthony Stamp
Description
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
BDRX Financial Timeline
Browse a chronological timeline of Biodexa Pharmaceuticals Plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Sept 2026
Stock split effective on 6 Apr 2026
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 27 Mar 2026
EPS came in at -$0.00 surpassing the estimated -$0.01 by +91.39%.
Earnings released on 12 Sept 2025
EPS came in at -$0.00 surpassing the estimated -$0.00 by +93.20%.
Stock split effective on 31 Jul 2025
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Apr 2025
EPS came in at -$0.01 falling short of the estimated -$0.01 by -5.25%.
Stock split effective on 4 Oct 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 26 Sept 2024
EPS came in at -$0.33 falling short of the estimated -$0.22 by -49.84%.
Earnings released on 19 Apr 2024
EPS came in at -$3.54 falling short of the estimated -$3.54 by -0.08%, while revenue for the quarter reached $106.02k , beating expectations by +0.22%.
Earnings released on 15 Sept 2023
EPS came in at -$2.77k , while revenue for the quarter reached $377.37k .
Stock split effective on 5 Jul 2023
Shares were split 1 : 80 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 28 Apr 2023
EPS came in at -$36.47k , while revenue for the quarter reached $283.92k .
Stock split effective on 27 Mar 2023
Shares were split 1 : 4 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 26 Sept 2022
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Sept 2022
EPS came in at -$23.99k , while revenue for the quarter reached $568.09k .
Earnings released on 26 Apr 2022
EPS came in at -$20.09k , while revenue for the quarter reached $238.76k .
Earnings released on 17 Sept 2021
EPS came in at -$28.13k , while revenue for the quarter reached $554.08k .
BDRX Stock Performance
Access detailed BDRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
